Signios Biosciences details how advanced single-cell and spatial transcriptomics support neuroscience research into Alzheimer’s, FTD, TBI, and Friedreich’s Ataxia, aiding new therapy development.
Today, we launch Signios Bio, a rebrand of what was previously known as MedGenome US Research Services. With a focus on scientific collaboration and breakthrough discovery, Signios Bio offers an integrated end-to-end suite of multiomic technologies.
Traumatic brain injury (TBI) poses complex challenges for researchers aiming to understand cellular responses post-injury. Professor Michelle H. Theus of Virginia Tech partnered with MedGenome to shed light on the cellular dynamics underlying injury progression and recovery on a murine TBI model using single-cell and spatial transcriptomics.
The immune system is a complex network of cells and molecules that defend the body against foreign invaders. Central to this defense mechanism are the T and B cells, which play a critical role in adaptive immunity.
The Human Cell Atlas (HCA) consortium has unveiled a landmark collection of over 40 studies from more than 100 countries, marking a significant leap in our understanding of the human body. Published across Nature and its affiliated journals, this updated release represents years of collaborative effort, utilizing cutting-edge single-cell and spatial transcriptomics technologies to map the cellular composition of tissues in unprecedented detail. These findings pave the way for breakthroughs in regenerative medicine, diagnostics, and the treatment of complex diseases.
Lung cancer remains the leading cause of cancer-related deaths globally, accounting for 18.4% of all cancer fatalities. Smoking is the primary cause of lung cancer, responsible for 80-90% of lung cancer deaths, though other risk factors like secondhand smoke, radon, asbestos, and family history also play roles. Research efforts to improve early detection, such as low-dose CT scans and biomarker tests, offer promise, and machine learning tools are being developed to enhance CT scan accuracy.
The adaptive immune system’s ability to recognize and neutralize a vast array of pathogens relies on the diversity of its lymphocyte repertoire. T and B lymphocytes, with their unique T cell receptors (TCRs) and B cell receptors (BCRs), are crucial for immunological memory and effective immune responses. This diversity allows the immune system to identify and combat a broad range of pathogens. Studying immune repertoire diversity offers valuable insights into disease mechanisms, therapeutic strategies, and vaccine development.
Illumina’s TSO 500 empowers comprehensive genomic profiling (CGP), unlocking crucial tumor biomarkers to drive precision medicine. By focusing on clinically relevant genomic regions, CGP provides in-depth analysis, accurately detects low-frequency mutations, and comprehensively characterizes tumors. This facilitates tailored treatment approaches, guiding therapy selection based on specific molecular profiles. Moreover, CGP enables non-invasive disease monitoring through circulating tumor DNA (ctDNA) analysis.
Single-cell sequencing offers unprecedented resolution for analyzing the unique molecular signatures of individual cells. By deconstructing the cellular landscape, it reveals hidden cell populations, tracks how cells differentiate, and identifies disease biomarkers. By dissecting the genomic, transcriptomic, and epigenetic landscape of single cells, researchers can now gain a deeper understanding of complex biological processes, disease mechanisms, and how patients respond to treatments. This method is essential for both basic and clinical research for unlocking the mysteries of cellular complexity and dynamic biological processes.
Short-read sequencing technologies have, without a doubt, revolutionized genomics. The ability to look at genetic variants at the base pair level and compare gene expression levels between normal and other conditions has made it possible to diagnose more diseases, develop more robust crops, and protect the biodiversity here on Earth.
